Maxime Dely on The vital Role of Plasma in Immune-Deficient Patients
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”Immunoglobulins: when plasma becomes a vital treatment for immune-deficient patients
Intravenous and subcutaneous immunoglobulins (IVIg, SCIg), produced exclusively from plasma donations, are life-saving medicines.
They replace or support the immune system in a wide range of conditions.
Main indications
- Primary immunodeficiencies (rare and severe congenital disorders)
- Secondary immunodeficiencies (after transplantation, chemotherapy, uncontrolled HIV, etc.)
- Autoimmune and neurological diseases (Guillain-Barré syndrome, myasthenia gravis, Kawasaki disease, immune thrombocytopenia, and more)
Worldwide
Today, millions of patients rely on immunoglobulin therapy every year.
Currently, the global demand is growing steadily (+5–7% annually), driven by broader indications and aging populations.
Unfortunately, there is no synthetic or recombinant alternative today — plasma is the only source.
Immunoglobulins are not only life-saving but also critical for maintaining quality of life in chronic patients.
Behind every infusion of immunoglobulins, there are thousands of plasma donations, transformed into precious medicines.
How can we raise more awareness about the growing importance of plasma-derived immunoglobulins, as global demand keeps rising?”
Stay updated on all scientific advances in the field of transfusion medicine with Hemostasis Today.
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:34Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
-
Jul 4, 2026, 15:20Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis